# Malignancies in Transplanted Patients

> **NCT02241564** · — · COMPLETED · sponsor: **Uppsala University** · enrollment: 95 (actual)

## Conditions studied

- Neoplasms

## Interventions

- **OTHER:** Referral to a multidisciplinary expert panel at the Uppsala University Hospital after tumor detection
- **DRUG:** Switch from calcineurin inhibitor to an mTOR inhibitor

## Key facts

- **NCT ID:** NCT02241564
- **Lead sponsor:** Uppsala University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2007-11
- **Primary completion:** 2017-06
- **Final completion:** 2017-06
- **Target enrollment:** 95 (ACTUAL)
- **Last updated:** 2017-10-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02241564

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02241564, "Malignancies in Transplanted Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02241564. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*